Form D · Pharmaceuticals
Cequent Pharmaceuticals Inc
Cambridge, MA · CIK 0001382090
Offering snapshot reported Oct 30, 2009 · SEC filing
- Reported sold
- $2.65M Offering amount: $10.8M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 16, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2009 | Initial | $2,653,536 | No comparison | 5 | SEC filing |
| Jan 8, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 8, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-96942
Source: Form D, filed Oct 30, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Hancock | Director |
| Herbert H. Hooper | Director |
| Chiang Li | Director, Executive |
| Eric Linsley | Director |
| Peter D. Parker | Director, Executive |
| Lauren Silverman | Director |
| Michael Taylor | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
One Kendall Square Building 700, First Floor
Cambridge, MA, 02139
Cambridge, MA, 02139